Cardiologychronic kidney diseaseFINEARTS-HF
Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF
By MedXY|Jan 16, 2026
A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline
